Opinion|Videos|June 9, 2025
Patient Experiences and Considerations for Axatilimab Therapy in Steroid-Refractory cGVHD
Panelists discuss how axatilimab demonstrates particularly good responses for gastrointestinal graft-vs-host disease (GVHD) and may improve sclerotic skin changes despite lower rates of overall skin response.
Advertisement
Episodes in this series
Clinical Experience with Newer Agents
The final segment covers the panelists’ perspectives on the AGAVE-201 trial data and early clinical experience with axatilimab. They note:
- Strong efficacy in gastrointestinal manifestations of chronic GVHD
- Efficacy in heavily pretreated patients (85% had prior ruxolitinib/ibrutinib/belumosudil)
- Different mechanism of action provides new options for refractory disease
- Early clinical experience shows good tolerability
- Potential adverse events to monitor: liver enzyme elevations, infusion reactions, periorbital edema
The panel discusses the practical aspects of intravenous administration (every 2 weeks) and their approaches to sequential vs combination therapy. Most prefer to add axatilimab while maintaining current therapy, then gradually tapering prior agents, though practices vary between centers.
Advertisement
Related to this article
Experts debate second-line tivozanib for advanced renal cell carcinoma, weighing PFS gains, tolerability, and whether continuing immunotherapy adds real benefit.
The designation expands the investigational immunotherapy’s development across tumor types for patients whose disease progresses after prior treatment, including immune checkpoint inhibition.
Phase 2b data show iopofosine I-131 drives deep, durable responses in relapsed Waldenström macroglobulinemia after BTK inhibitors, with manageable cytopenias.
The RELIGHT study found that adding retlirafusp alfa to chemotherapy extended overall and progression-free survival in previously untreated gastric and GEJ cancers.
Gary Simmons, DO, MSHA, discusses outpatient CAR T-cell therapy in the community, the operational and payer bottlenecks his practice has faced, and advice for colleagues.
During a virtual event, Neil M. Iyengar, MD, and participants discussed how approvals for trastuzumab deruxtecan before and after surgery complicate sequencing for patients with HER2-positive early breast cancer.
The oral KRAS G12D inhibitor VS-7375 elicited clinical responses across patients with KRAS G12D–mutant pancreatic, lung, and colorectal cancer.
ASH updates myelofibrosis care with expanded molecular testing, earlier transplant consultation, tailored JAK inhibitor use, anemia strategies, and aspirin guidance to reduce clot risk.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Amivantamab vs. Emerging EGFR Bispecifics in HNSCC
2
Durability of PFS and OS Benefit vs. Historical Control
3
ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types
4
Retlirafusp Alfa Improves Overall Survival in Phase 3 Trial of HER2– Gastric Cancer
5